title: Focus on polypharmacy in schizophrenia: does anyone truly benefit?
authors.affiliation: Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA. goff@psych.mgh.harvard.edu
authors.forename: Donald C
authors.initials: DC
authors.lastname: Goff
authors.forename: Oliver
authors.initials: O
authors.lastname: Freudenreich
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D065127:Dopamine D2 Receptor Antagonists; D004359:Drug Therapy, Combination; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists